Home › Funds › Palo Alto Investors LP › NVCR
Palo Alto Investors LP position in NVCR
NOVOCURE LTD · Health Care
Palo Alto Investors LP reported holding 1,209,774 shares of NVCR (NOVOCURE LTD) in its Q3 2026 13F filing — a position valued at US$19.3M, representing 2.87% of its reported portfolio and ranking #14 among its reported holdings. Palo Alto Investors LP has disclosed NVCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's NVCR position evolved
Palo Alto Investors LP first disclosed a stake in NVCR in Q3 2023 at 660,275 shares (US$10.7M). The position peaked in Q4 2024 at 814,191 shares, worth US$24.3M. Across 13 filings, Palo Alto Investors LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,209,774 shares valued at US$19.3M — a reduction of -70,665 shares quarter over quarter.. Notable position changes include a 37% increase in Q4 2024 (shares fell 40% over the following quarter), a 31% increase in Q3 2025 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 660.27K | $10.66M | New |
| Q4 2023 | 561.91K | $8.39M | Reduce |
| Q1 2024 | 561.91K | $8.78M | Hold |
| Q2 2024 | 561.91K | $9.63M | Hold |
| Q3 2024 | 593.54K | $9.28M | Add |
| Q4 2024 | 814.19K | $24.26M | Add |
| Q1 2025 | 1.00M | $17.86M | Add |
| Q2 2025 | 962.40K | $17.13M | Reduce |
| Q3 2025 | 1.26M | $16.23M | Add |
| Q4 2025 | 1.30M | $16.80M | Add |
| Q1 2026 | 1.28M | $13.96M | Reduce |
| Q2 2026 | 1.28M | $19.40M | Hold |
| Q3 2026 | 1.21M | $19.30M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NVCR and 13F data
NVCR (NOVOCURE LTD) is a Health Care company. 26 other funds we track also report a position in NVCR — the largest reported positions include Soleus Capital Management, L.P. (US$150.3M), C WorldWide Group Holding A/S (US$15.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NVCR
- Soleus Capital Management, L.P. 9.43M sh · $150.34M · Q3 2026
- C WorldWide Group Holding A/S 971.78K sh · $15.50M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held NVCR?
Palo Alto Investors LP has disclosed NVCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Palo Alto Investors LP's current position in NVCR?
As of Q3 2026, Palo Alto Investors LP holds 1.21M shares of NVCR (NOVOCURE LTD), valued at $19.30M, representing 2.87% of its reported portfolio and ranking #14.
Has Palo Alto Investors LP been buying or selling NVCR?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in NVCR. The position peaked in Q4 2024 at 814.19K shares.
Which other funds hold NVCR?
Other major institutional holders of NVCR include Soleus Capital Management, L.P., C WorldWide Group Holding A/S, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.